IDEXX Laboratories, Inc. (NASDAQ:IDXX) Holdings Raised by Victory Capital Management Inc.

Victory Capital Management Inc. grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 180,165 shares of the company's stock after purchasing an additional 7,034 shares during the period. Victory Capital Management Inc. owned about 0.22% of IDEXX Laboratories worth $75,660,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in IDXX. Cibc World Markets Corp boosted its position in shares of IDEXX Laboratories by 13.1% during the fourth quarter. Cibc World Markets Corp now owns 14,744 shares of the company's stock worth $6,096,000 after buying an additional 1,709 shares during the period. Horizon Investments LLC raised its holdings in shares of IDEXX Laboratories by 3.3% in the 4th quarter. Horizon Investments LLC now owns 1,296 shares of the company's stock worth $536,000 after purchasing an additional 42 shares during the period. Intech Investment Management LLC increased its holdings in shares of IDEXX Laboratories by 165.2% in the fourth quarter. Intech Investment Management LLC now owns 6,421 shares of the company's stock worth $2,655,000 after purchasing an additional 4,000 shares during the period. Harvest Fund Management Co. Ltd raised its stake in shares of IDEXX Laboratories by 27.1% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 4,819 shares of the company's stock valued at $1,947,000 after acquiring an additional 1,028 shares during the last quarter. Finally, iA Global Asset Management Inc. increased its stake in shares of IDEXX Laboratories by 18.6% during the fourth quarter. iA Global Asset Management Inc. now owns 13,763 shares of the company's stock valued at $5,690,000 after purchasing an additional 2,158 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.98% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on IDXX shares. Wall Street Zen raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price objective for the company. Leerink Partners raised their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday. Morgan Stanley boosted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Finally, Stifel Nicolaus upped their target price on IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a research report on Wednesday, July 2nd. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and an average target price of $560.33.

IDEXX Laboratories Stock Down 0.4%

Shares of NASDAQ IDXX opened at $518.71 on Friday. The firm has a market capitalization of $41.71 billion, a PE ratio of 47.94, a price-to-earnings-growth ratio of 3.80 and a beta of 1.54. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $549.52. The firm's 50-day moving average is $523.12 and its 200-day moving average is $462.00. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The firm had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. During the same quarter in the prior year, the firm earned $2.71 EPS. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.